Renaissance Capital logo

VectivBio Holding Priced, Nasdaq: VECT

Swiss Phase 3 biotech developing therapies for rare gastrointestinal disorders.

Industry: Health Care

Latest Trade: $15.25 0.00 (0.0%)

First Day Return: +42.5%

Return from IPO: -10.3%

Industry: Health Care

We are a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe rare conditions for which there is a significant unmet medical need. We are led by an experienced management team with a strong track record in the biotechnology and pharmaceutical industry. Our goal is to become a leading, patient-centric, fully integrated global rare disease company. Our current product pipeline is focused on rare gastrointestinal, or GI, disorders, and we intend to in-license or acquire additional transformational, differentiated rare disease assets. Our product candidate, apraglutide, is a next generation, long-acting synthetic peptide analog of glucagon-like peptide-2, or GLP-2, which we are developing as a differentiated therapeutic for a range of rare GI diseases, with an initial focus on short bowel syndrome, or SBS. Based on our preclinical and clinical data to date, we believe that apraglutide has the potential to advance the treatment of SBS intestinal failure, or SBS-IF, by establishing less frequent dosing and improve clinical outcomes. Apraglutide is currently being evaluated in a global Phase 3 clinical trial for the treatment of patients with SBS-IF. We also plan to evaluate apraglutide’s therapeutic potential in additional rare GI conditions, such as graft versus host disease, that could benefit from GLP-2 activation.
more less
IPO News for VectivBio Holding
more
IPO Data
IPO File Date 03/19/2021
Offer Price $17.00
Price Range $16.00 - $18.00
Offer Shares (mm) 7.5
Deal Size ($mm) $128
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 04/08/2021
Offer Price $17.00
Price Range $16.00 - $18.00
Offer Shares (mm) 7.5
Deal Size ($mm) $128
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters Basel, Switzerland
Founded 2019
Employees n/a
Website vectivbio.com